Abstract

  Mammary analogue secretory carcinoma of salivary gland (MASC) is a recently described tumor, with small number of published cases. Less than three hundred cases have been reported in the literature and only very few of them of these cases have been reported in minor salivary glands. We present a case of a 71-years old male who was diagnosed with MASC tumor presenting in a minor salivary gland and briefly review of literature. My provisional diagnosis after careful histopathological examination of the tumor sections was either Acinic cell carcinoma or mammary analogue of secretory carcinoma of salivary gland. The final diagnosis of MASC was considered after immunohistochemical staining of tumor section with DOG-1 and mammaglobin. The gold standard for MASC diagnosis is cytogenetics, with the majority having a translocation t (12;15)(p133;q25). Although the tumor may present with different histological grading, the treatment plan could be modified in some selected cases according to the grade of the tumor.

Keywords: DOG-1; Mammary Analogue Secretory Carcinoma (MASC); Salivary Gland

References

1. , et al. “Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity”. The American Journal of Surgical Pathology 34.5 (2010): 599-608.
2. , et al. “Secretory carcinoma of the breast”. Journal of Breast Health 12.4 (2016): 174.
3. Bishop JA. “Unmasking MASC: bringing to light the unique morphologic, immunohistochemical and genetic features of the newly recognized mammary analogue secretory carcinoma of salivary glands”. &N Pathology 7.1 (2013): 35-39.
4. Bishop JA., et al. “Cytopathologic features of mammary analogue secretory carcinoma”. Cancer Cytopathology 5 (2013): 228-233.
5. Chiosea SI., et al. “Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands”. Histopathology3 (2012): 387-394.
6. Connor A., et al. “Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity”. The American Journal of Surgical Pathology1 (2012): 27-34.
7. Khurram SA., et al. “Cytogenetic and immunohistochemical characterization of mammary analogue secretory carcinoma of salivary glands”. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 6 (2016): 731-742.
8. Skalova A., et al. “Newly described salivary gland tumors”. Modern Pathologys1 (2017): S27.
9. Mariano FV., et al. “Mammary analogue secretory carcinoma of salivary glands is a lipid‐rich tumour, and adipophilin can be valuable in its identification”. Histopathology4 (2013): 558-567.
10. Suzuki K., et al. “Mammary analogue secretory carcinoma presenting as a cervical lymph node metastasis of unknown primary site: a case report”. Oncology Case Reports Journal1 (2017): 192-198.
11. Sethi R., et al. “Mammary analogue secretory carcinoma: update on a new diagnosis of salivary gland malignancy”. The Laryngoscope 1 (2014): 188-195.
12. Hwang MJ., et al. “A rare malignancy of the parotid gland in a 13-year-old Taiwanese boy: case report of a mammary analogue secretory carcinoma of the salivary gland with molecular study”. Medical Molecular Morphology 1 (2014): 57-61.
13. Khalele BA. “Systematic review of mammary analog secretory carcinoma of salivary glands at 7 years after description”. &N 39.6 (2017): 1243-1248.
14. Zardawi IM and Hook P. “Mammary analogue secretory carcinoma of minor salivary glands”. Pathology - Journal of the RCPA 7 (2014): 667-669.
15. Ngouajio AL., et al. “A systematic review including an additional pediatric case report: pediatric cases of mammary analogue secretory carcinoma”. International Journal of Pediatric Otorhinolaryngology 100 (2017): 187-193.
16. Brandwein-Gensler M., et al. “Low-grade salivary duct carcinoma: description of 16 cases”. The American Journal of Surgical Pathology 8 (2004): 1040-1044.
17. Shah AA., et al. “Morphology in conjunction with immunohistochemistry is sufficient for the diagnosis of mammary analogue secretory carcinoma”. &N Pathology 9.1 (2015): 85-95.
18. Skalova A. “Mammary analogue secretory carcinoma of salivary gland origin: an update and expanded morphologic and immunohistochemical spectrum of recently described entity”. &N Pathology 7.1 (2013): 30-36.
19. O’Neill ID. “t (11; 19) translocation and CRTC1-MAML2 fusion oncogene in mucoepidermoid carcinoma”. Oral Oncology1 (2009): 2-9.
20. Castle JT., et al. “Polymorphous low grade adenocarcinoma: a clinicopathologic study of 164 cases”. Interdisciplinary International Journal of the American Cancer Society2 (1999): 207-219.
21. Patel KR., et al. “Mammaglobin and S-100 immunoreactivity in salivary gland carcinomas other than mammary analogue secretory carcinoma”. Human Pathology11 (2013): 2501-2508.
22. Griffith CC., et al. “The cytological features of mammary analogue secretory carcinoma: a series of 6 molecularly confirmed cases”. Cancer Cytopathology 5 (2013): 234-241.
23. Salat H., et al. “Mammary analogue secretory carcinoma of the parotid gland: a third world country perspective—a case series”. Case Reports in Otolaryngology (2015): 2015.
24. Takeda M., et al. “Cytopathological features of mammary analogue secretory carcinoma—Review of literature”. Diagnostic Cytopathology 2 (2015): 131-137.
25. Stevens TM and Parekh V. “Mammary analogue secretory carcinoma”. Archives of Pathology and Laboratory Medicine 9 (2016): 997-1001.

Citation

Citation: Heba Ahmed Saleh. “Mammary Analogue Secretory Carcinoma of the Buccal Mucosa: Case Report and Review of the Literature". Acta Scientific Clinical Case Reports 1.11 (2020): 32-39.

Copyright

Copyright: © 2020 Heba Ahmed Saleh. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.